Zehra Tombul

Zehra Tombul

Auto-generated profile, based on publicly available information

Zehra Tombul

Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
ZTZehra Tombul
Zehra Tombul
WBWaled Bahaj
Waled Bahaj
MOMerve Ozturk
Merve Ozturk
BPBhavisha Patel
Bhavisha Patel
ATAhmet Toprak
Ahmet Toprak
TBTaha Bat
Taha Bat

25 August 2025 in Blood Neoplasia
Verified
Journal Article
Open access
ATAhmet Celal Toprak
Ahmet Celal Toprak
MMMutlu Mete
Mutlu Mete
JSJulia J. Shi
Julia J. Shi
DBDaria V. Babushok
Daria V. Babushok
CGCarmelo Gurnari
Carmelo Gurnari
TBTaha Bat
Taha Bat
Patients with acquired aplastic anemia (AA) treated with immunosuppressive therapy (IST) face up to a 20% long-term risk of developing secondary myeloid neoplasms (sMNs), including acute myeloid leukemia and myelodysplastic syndromes. Although hematopoietic stem cell transplantation (HSCT) is curative and prevents sMNs, older patients and those lacking suitable donors have historically received IST as first-line therapy. Recent improvements in HSCT outcomes have expanded transplant eligibility, highlighting the need for tools to better identify patients at high risk for sMN. Validated predictive models could help guide early HSCT consideration or tailor surveillance strategies. We developed 2 binary machine learning models to predict sMN development in patients with acquired AA at clinically relevant time points: diagnosis (model 1) and 6 months after IST response (model 2). We analyzed data from 275 adult patients with AA treated at University of Texas Southwestern, Cleveland Clinic, and the Hospital of the University of Pennsylvania between 1975 and 2023. Seventy-nine clinical variables were collected, including demographics, somatic mutations, and treatment response. Neural networks were trained with leave-1-out crossvalidation. Both models achieved strong performance (area under the curve, 0.82; sensitivity, 0.82, specificity, 0.73). Shared key predictors included DNMT3A mutation, CUX1 mutation, total mutation count, and age. TET2 mutation was specific to model 1; paroxysmal nocturnal hemoglobinuria clone presence was unique to model 2. High-risk classification was significantly associated with worse overall survival (P < .0001). These findings support the feasibility of machine learning-based sMN risk prediction in AA. With training on larger data sets and external validation, these models may support individualized decision-making around HSCT and post-IST surveillance.